Fasnall, a Selective FASN Inhibitor, Shows Potent Anti-tumor Activity in the MMTV-Neu Model of HER2(+) Breast Cancer.

Many tumors are dependent on de novo fatty acid synthesis to maintain cell growth. Fatty acid synthase (FASN) catalyzes the final synthetic step of this pathway, and its upregulation is correlated with tumor aggressiveness. The consequences and adaptive responses of acute or chronic inhibition of essential enzymes such as FASN are not fully understood. Herein we identify Fasnall, a thiophenopyrimidine selectively targeting FASN through its co-factor binding sites. Global lipidomics studies with Fasnall showed profound changes in cellular lipid profiles, sharply increasing ceramides, diacylglycerols, and unsaturated fatty acids as well as increasing exogenous palmitate uptake that is deviated more into neutral lipid formation rather than phospholipids. We also showed that the increase in ceramide levels contributes to some extent in the mediation of apoptosis. Consistent with this mechanism of action, Fasnall showed potent anti-tumor activity in the MMTV-Neu model of HER2(+) breast cancer, particularly when combined with carboplatin.

[1]  H. Muratsubaki,et al.  Rapid purification of yeast cytoplasmic fumarate reductase by affinity chromatography on blue sepharose CL-6B. , 1994, Preparative biochemistry.

[2]  Z. Siddik,et al.  Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. , 1984, Cancer research.

[3]  T. Haystead,et al.  Both insulin and epidermal growth factor stimulate lipogenesis and acetyl-CoA carboxylase activity in isolated adipocytes. Importance of homogenization procedure in avoiding artefacts in acetyl-CoA carboxylase assay. , 1986, The Biochemical journal.

[4]  M. Sivaraja,et al.  Imidazopyridine-Based Fatty Acid Synthase Inhibitors That Show Anti-HCV Activity and in Vivo Target Modulation. , 2013, ACS medicinal chemistry letters.

[5]  Sebastian Munck,et al.  De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. , 2010, Cancer research.

[6]  D. Bussiere,et al.  Targeting the purinome. , 2009, Methods in molecular biology.

[7]  M. Artola,et al.  New synthetic inhibitors of fatty acid synthase with anticancer activity. , 2012, Journal of medicinal chemistry.

[8]  T. Haystead,et al.  Effects of the tumour promoter okadaic acid on intracellular protein phosphorylation and metabolism , 1989, Nature.

[9]  Megha,et al.  Ceramide Selectively Displaces Cholesterol from Ordered Lipid Domains (Rafts) , 2004, Journal of Biological Chemistry.

[10]  A. Isacchi,et al.  The generation of purinome-targeted libraries as a means to diversify ATP-mimetic chemical classes for lead finding , 2012, Molecular Diversity.

[11]  P. Morin,et al.  Activation of fatty acid synthesis during neoplastic transformation: role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. , 2002, Experimental cell research.

[12]  Philip F. Hughes,et al.  Fluorescence linked enzyme chemoproteomic strategy for discovery of a potent and selective DAPK1 and ZIPK inhibitor. , 2013, ACS chemical biology.

[13]  Philip F. Hughes,et al.  A highly selective Hsp90 affinity chromatography resin with a cleavable linker. , 2012, Bioorganic & medicinal chemistry.

[14]  R. Brugada,et al.  Novel anti‐fatty acid synthase compounds with anti‐cancer activity in HER2+ breast cancer , 2010, Annals of the New York Academy of Sciences.

[15]  D. Epps,et al.  Rapid separation of lipid classes in high yield and purity using bonded phase columns. , 1985, Journal of lipid research.

[16]  J. Swinnen,et al.  The Lipogenic Switch in Cancer , 2009 .

[17]  G. Chu,et al.  Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. , 1994, The Journal of biological chemistry.

[18]  P. Visca,et al.  Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients , 1996, Cancer.

[19]  N. Magné,et al.  Pharmacokinetics of low-dose carboplatin and applicability of a method of calculation for estimating individual drug clearance. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  Ken Saito,et al.  Mechanism of apoptosis induced by the inhibition of fatty acid synthase in breast cancer cells. , 2006, Cancer research.

[21]  Timm Maier,et al.  The Crystal Structure of a Mammalian Fatty Acid Synthase , 2008, Science.

[22]  T. Haystead.  The purinome, a complex mix of drug and toxicity targets. , 2006, Current topics in medicinal chemistry.

[23]  Martin L Read,et al.  Discovery of GSK837149A, an inhibitor of human fatty acid synthase targeting the β‐ketoacyl reductase reaction , 2008, The FEBS journal.

[24]  I. Shih,et al.  Trophoblastic neoplasms express fatty acid synthase, which may be a therapeutic target via its inhibitor C93. , 2009, The American journal of pathology.

[25]  D. Lydall,et al.  Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. , 1986, Cancer research.

[26]  C. Townsend,et al.  Application of a flexible synthesis of (5R)-thiolactomycin to develop new inhibitors of type I fatty acid synthase. , 2005, Journal of medicinal chemistry.

[27]  E. Adrover,et al.  Carboplatin: an active drug in metastatic breast cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  C. Townsend,et al.  Synthesis and antitumor activity of an inhibitor of fatty acid synthase , 2000 .

[29]  Jeffrey W. Smith,et al.  Novel antagonists of the thioesterase domain of human fatty acid synthase , 2007, Molecular Cancer Therapeutics.

[30]  C. Long,et al.  Observations on the affinity for carnitine, and malonyl-CoA sensitivity, of carnitine palmitoyltransferase I in animal and human tissues. Demonstration of the presence of malonyl-CoA in non-hepatic tissues of the rat. , 1983, The Biochemical journal.

[31]  G. Ronnett,et al.  C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[32]  C. Townsend,et al.  Fatty acid synthase inhibition activates AMP-activated protein kinase in SKOV3 human ovarian cancer cells. , 2007, Cancer research.

[33]  W. Tian.  Inhibition of fatty acid synthase by polyphenols. , 2006, Current medicinal chemistry.

[34]  Ramona N Plant,et al.  A human fatty acid synthase inhibitor binds β-ketoacyl reductase in the keto-substrate site. , 2014, Nature chemical biology.

[35]  P. Leder,et al.  Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene , 1988, Cell.

[36]  H. Kalbacher,et al.  De novo lipogenesis in health and disease. , 2014, Metabolism: Clinical and Experimental.

[37]  H. Aguilar,et al.  Novel Inhibitors of Fatty Acid Synthase with Anticancer Activity , 2009, Clinical Cancer Research.

[38]  M. Fukata,et al.  Dynamic protein palmitoylation in cellular signaling. , 2009, Progress in lipid research.

[39]  E. Gabrielson,et al.  Selective Inhibition of Fatty Acid Synthase for Lung Cancer Treatment , 2007, Clinical Cancer Research.

[40]  D. Bussiere,et al.  Targeting cancer: the challenges and successes of structure-based drug design against the human purinome. , 2006, Current topics in medicinal chemistry.

[41]  W. Tian,et al.  Green tea epigallocatechin gallate: a natural inhibitor of fatty-acid synthase. , 2001, Biochemical and biophysical research communications.

[42]  M. Numata,et al.  Simple method for isolation of glyceraldehyde 3-phosphate dehydrogenase and the improvement of myofibril gel properties. , 2011, Animal science journal = Nihon chikusan Gakkaiho.

[43]  Di Chen,et al.  A novel prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate as a potential anticancer agent. , 2007, Cancer research.

[44]  H. Aguilar,et al.  A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines , 2011, Breast Cancer Research.

[45]  J. Swinnen,et al.  Increased lipogenesis in cancer cells: new players, novel targets , 2006, Current opinion in clinical nutrition and metabolic care.